CpG DNA as a vaccine adjuvant
- PMID: 21506647
- PMCID: PMC3108434
- DOI: 10.1586/erv.10.174
CpG DNA as a vaccine adjuvant
Abstract
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.
Figures
References
-
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. - PubMed
-
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010;11(5):373–384. - PubMed
-
- Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164):819–826. - PubMed
-
- Paul WE. Fundamental Immunology. New York, NY, USA: Raven Press; 1993.
Website
-
- Phase I study of the safety and immunogenicity of BSAM-2/ alhydrogel(registered trademark)+CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria in adults in the US and Mali. http://clinicaltrials.gov/ct2/show/NCT00889616.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources